A novel therapeutic vaccine of GM-CSF/TNF[alpha] surface-modified RM-1 cells against the orthotopic prostatic cancer

• Published in: Vaccine Vol. 28; no. 31; p. 4937
• Main Authors: Yin, Weihua, He, Qiushan, Hu, Zhiming, Chen, Zhong, Qifeng, Mao, Zhichun, Song, Zhihui, Qu, Xiaoxia, Nie, Li, Jinlong, Gao, Jimin
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 12.07.2010
• Subjects: Biological activity; Bone marrow; Cytokines; Cytotoxicity; Ethanol; Lymphocytes; Melanoma; Prostate cancer; Proteins; Vaccines
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2010.05.038

A novel therapeutic vaccine against prostate cancer was developed by simultaneous immobilization of streptavidin-tagged bioactive GM-CSF and TNFα on the biotinylated surface of 30% ethanol-fixed RM-1 prostatic cancer cells. This study showed that the GM-CSF/TNFα-doubly surface-modified vaccine significantly extended the survival in the orthotopic model of RM-1 prostate cancer, and was superior to single GM-CSF- or TNFα-surface-modified vaccine. Moreover, the splenocytes from the GM-CSF/TNFα-vaccine-treated mice showed the most potent cytotoxicity on RM-1 cells and the highest production of RM-1-specific IFNγ. In addition, more CD4+and CD8+T cells infiltrated into the tumor sites in the GM-CSF/TNFα-vaccine-treated mice than in the GM-CSF- or TNFα-vaccine-treated mice. Therefore, our study demonstrated that the efficacy of RM-1 prostate cancer cell vaccine could be improved by conjugating both GM-CSF and TNFα simultaneously on the surface of cancer cells, and that this modification thus has a potential translational significance.